Bristol, UK (PRWEB) March 15, 2010
Tocris Bioscience announced today that it has entered into an agreement with Pfizer which will result in a wide range of Pfizer compounds being made available to the global research community.
For the first time, scientists involved in preclinical research will now be able to purchase authentic, fully-licensed, non-formulated, sunitinib, varenicline and other Pfizer compounds as off-the shelf products for use in their preclinical research studies. In addition, a significant number of Pfizer's ‘literature compounds’ - biologically active small molecules that have not progressed from development to clinical use - will also be offered for sale.
Typically supplied in 10 and 50 milligram pack sizes ideally suited for preclinical laboratory research applications, the availability of these products through Tocris will benefit scientists working in a diverse range of fields, including neuroscience, cancer and metabolic disease.
"We are pleased to be working with Tocris" noted Richard Connell, VP of External Research Solutions CoE at Pfizer. "Tocris has an excellent track record of respecting Pfizer’s intellectual property while making a range of important compounds available to the research community. We appreciate the innovative and creative ways they listen to and serve life science researchers in academia and industry".
Laurence Ede, Tocris' Managing Director, added "Pfizer's portfolio of compounds is world class and I'm very excited that Tocris has the opportunity to provide preclinical researchers with access to these materials. These important new additions perfectly complement Tocris' range of high purity compounds, which are used by scientists worldwide in the furtherance of biomedical research. We are delighted to enter into this agreement with Pfizer and look forward to working in close partnership together going forward."